The United States is about to launch its first trial of a coronavirus vaccine.

!-- webeditor: page title . . . March 9, 2020 / -- Moderna, Inc. (NASDAQ: MRNA) is a clinical biotech company whose pioneering Messenger RNA (MRNA) therapies and vaccines have created a new generation of transformative drugs for patients.
the company recently announced that it has produced the first batch of MRA-1273, the company's vaccine against the new coronavirus for human use.
mRNA-1273 has been shipped to the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for clinical Phase 1 trials in the United States.
mRNA-1273 is an mRNA vaccine for a new coronavirus that encodes a pre-fusion stable form of spike (S) protein, in collaboration with researchers at the NIAID Vaccine Research Center (VRC).
the vaccine was funded by the Alliance for Innovation in Epidemiological Preparedness (CEPI).
photo source: Designing the vaccine in the form of mRNA allows Moderna to quickly track the development process because the company does not need to separate and modify live samples of SARS-CoV-2, just as it does not need to separate and modify more traditional vaccines.
volunteers will receive two vaccinations in their upper arms, with a 28-day interval between injections.
45 participants will be divided into three groups, each receiving a different dose of the vaccine.
during the 14-month study, volunteers will be asked to participate in 11 face-to-face study visits, each of which will receive $100, up to a total of $1,100.
after the initial safety trials, the effectiveness of the vaccine must be tested in a larger population in subsequent trials before it can be widely distributed.
, researchers around the world will continue to study possible treatments to help people infected with the virus.
currently, COVID-19 patients will receive supportive treatment to address the symptoms of the disease.
I would like to thank the entire Moderna team for their extraordinary efforts in this global health emergency at a record pace."
, Chief Technology Operations and Quality Officer at
Moderna, said: "By working with NIAID and CEPI, we can complete a clinical batch within 42 days.
would not have been possible without our Norwood manufacturing base.
Norwood uses cutting-edge technology to make operations more flexible and ensure high quality standards for clinical grade materials.
"the company's Norwood manufacturing plant manufactures Modelna's mRNA development candidates, including vaccines and therapeutic drugs.
, the company has produced and released more than 100 batches of products for human clinical trials from its Norwood site.
mRNA-1273 is part of the company's core vaccine prevention model, which has conducted six positive Phase 1 clinical trials of six different vaccines over the past four years.
about mRNA-1273mRNA-1273 is an mRNA vaccine against a new coronavirus that encodes a pre-fusion stable form of spike (S) protein, designed by Moderna in collaboration with NIAID.
S protein complex is necessary for membrane fusion and host cell infection and has become a target for coronavirus vaccines for Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).
about coronavirus coronavirus is a class of viruses that can cause respiratory diseases, including MERS and SARS.
can be transmitted from animal to person and can evolve into strains previously undiscovered in humans.
January 7, 2020, a new coronavirus was identified as the cause of cases of COVID-19 pneumonia.
Modelna, a vaccine model for Moderna, designed the company's preventive vaccine model for infectious diseases.
more than 1000 participants from the United States, Europe and Australia participated in moderna's clinical study of infectious disease vaccines under the guidance of U.S. health authorities.
based on the clinical experience of six Phase I studies, the company has designated preventive vaccines as a core approach and intends to accelerate the development of its infectious disease candidate vaccines.
Potential benefits of an mRNA approach to vaccine prevention include a stronger immune response to simulate natural infection stimuli, the ability to combine multiple mRNAs into a single vaccine, the ability to respond quickly to emerging pandemic threats, and the platform agility derived from the design and production of mRNA vaccines.
Moderna has built a fully integrated manufacturing facility in Norwood, Massachusetts, fulfilling its commitment to a technology platform.
Photo Source: There are currently 9 candidate developments for vaccine prevention models, including: Vaccines to Prevent Severe Respiratory Infections: Respiratory Syncytial Virus (RSV) Vaccines for the Elderly (mRNA-1777 and Merck's mRNA-1172/V172); (mRNA-1345); human pulmonary virus and para-flu virus type 3 (hMPV/PIV3) vaccine (mRNA-1653); new coronavirus vaccine (mRNA-1273); influenza H7N9 (mRNA-1851).
vaccine against mother-to-child transmission of serious infections: cytovirus (CMV) vaccine (mRNA-1647);
vaccine against common viral infections: EV virus (EBV) vaccine (mRNA-1189) To date, Moderna has confirmed positive for phase 1 of six preventive vaccines (H10N8, H7N9, RSV, chikungi, hMPV/PIV3, and CMV).
Medena's CMV vaccine is currently in phase 2 dose selection studies.
the first phase of the Study on the Zika Vaccine (mRNA-1893) in Moderna and was awarded the FDA Fast Track title.
() !--/ewebeditor:page--!--ewebeditor:page title="--reference: 1. Moderna Ships mRNA Vaccines Novel Coronavirus (mRNA-1273) for Phase 1 Study (2) FIRSTVIRUS TRIAL IN US IS RECRUITING VOLUNTEERS !--/ewebeditor: